Overview
William Griffiths practices in Cambridge, United Kingdom. Mr. Griffiths is rated as an Advanced expert by MediFind in the treatment of Hepatocerebral Degeneration. His top areas of expertise are Hemochromatosis, Hepatocerebral Degeneration, Wilson Disease, Common Variable Immune Deficiency, and Liver Transplant.
His clinical research consists of co-authoring 30 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hepatocerebral Degeneration.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- HemochromatosisMr. Griffiths isAdvanced. Learn about Hemochromatosis.
- Hepatocerebral DegenerationMr. Griffiths isAdvanced. Learn about Hepatocerebral Degeneration.
- Wilson DiseaseMr. Griffiths isAdvanced. Learn about Wilson Disease.
- Experienced
- Alpha-1 Antitrypsin Deficiency (AATD)Mr. Griffiths isExperienced. Learn about Alpha-1 Antitrypsin Deficiency (AATD).
- Blau SyndromeMr. Griffiths isExperienced. Learn about Blau Syndrome.
- CholestasisMr. Griffiths isExperienced. Learn about Cholestasis.
- CirrhosisMr. Griffiths isExperienced. Learn about Cirrhosis.
- Common Variable Immune DeficiencyMr. Griffiths isExperienced. Learn about Common Variable Immune Deficiency.
- Immunodeficiency with Hyper IgM Type 1Mr. Griffiths isExperienced. Learn about Immunodeficiency with Hyper IgM Type 1.